|
Issues (Archived 4/29/2009)
Encouraging Results for Prostate Cancer Vaccine Released
Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, National Institutes of Health (NIH), led the scientific team that developed PROSTVAC, a prostate cancer vaccine technology. PROSTVAC is currently Bavarian Nordic’s (BN) lead prostate cancer vaccine candidate. Bavarian Nordic Immunotherapeutics (BNIT, U.S. subsidiary of BN) has a license from the NIH to further develop the vaccine. BN recently released encouraging clinical data for the vaccine at the Genitourinary Cancers Symposium (GU) on February 26-28, 2009 in Orlando, Florida. This announcement is the first among several other study results that are expected to be released in 2009. For further details, please read the Press Release from BN.
Archived Issues..
|
